-
141
A Systematic Review of the Stability of Extemporaneous Pediatric Oral Formulations
Published 2021-01-01“…Oral extemporaneous formulations from commercially available dosage forms and pure drugs were considered. According to the United States and British Pharmacopeia (USP and BP), most extemporaneous formulations are accepted as chemically stable if they maintain ≥90% of the original drug amount, physically stable if there is no apparent change in physical property, and microbiologically stable if there is no growth of microorganisms in prepared formulations. …”
Get full text
Article -
142
PPARs: Protectors or Opponents of Myocardial Function?
Published 2015-01-01“…Over 5 million people in the United States suffer from the complications of heart failure (HF), which is a rapidly expanding health complication. …”
Get full text
Article -
143
-
144
-
145
-
146
-
147
-
148
-
149
Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies
Published 2024-11-01Get full text
Article -
150
-
151
-
152
-
153
-
154
-
155
Update on Babesiosis
Published 2009-01-01“…Over the last 50 years, the epidemiology of human babesiosis has changed from a few isolated cases to the establishment of endemic areas in the northeastern and midwestern United States. Episodic cases are reported in Europe, Asia, Africa, and South America. …”
Get full text
Article -
156
Health information-seeking on Reddit, by people who use opioids
Published 2024-06-01“…In the most recent year that data is available, 101,035 people died from drug overdoses in the United States. For people who use drugs, obtaining treatment remains a significant barrier due to issues of fear, stigmatisation, and illegality. …”
Get full text
Article -
157
Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma
Published 2025-02-01Get full text
Article -
158
Unlocking biological complexity: the role of machine learning in integrative multi-omics
Published 2024-11-01Get full text
Article -
159
Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis
Published 2015-01-01“…**Background:** Approximately 3.75% of cases of blindness in the United States are caused by uveitis. Incurred clinical costs and lost productivity related to vision loss in these cases totals $3.58 billion annually. …”
Get full text
Article -
160